文献速递皮肤肿瘤

血清S100B蛋白月度变化预测高危黑色素瘤转移

Monthly changes in serum levels of S100B protein as a predictor of metastasis development in high-risk melanoma patients.
PubMed 文献 · J Eur Acad Dermatol Venereol · 2020-02-21

这项回顾性队列研究纳入289例IIB、IIC或III期黑色素瘤患者,随访中位44个月,45%发生转移。经典方法(单次S100B超过截断值)检测复发的敏感性和特异性分别为35.7%和92.5%;对S100B正常复发的患者,基于月度变化的新方法敏感性和特异性分别为41.1%和92.4%,可检出经典方法漏诊的复发。

要点

  • 高危黑色素瘤随访中,S100B正常范围内月度上升提示疾病进展。
  • 经典单次超标法敏感性低(35.7%),易漏诊S100B正常复发。
  • 月度变化法可补充检出经典方法漏诊的复发。

核心结论

  • 高危黑色素瘤患者随访期间,血清S100B在正常范围内上升可作为疾病进展的重要线索。

研究设计与样本

  • 回顾性队列研究,纳入2003年1月至2013年7月初诊为IIB、IIC和III期黑色素瘤的患者。
  • 共289例患者随访44个月(IQR 17-73),按每3-6个月进行影像学和血清S100B检测的强化方案随访。

主要发现

  • 随访期间45%发生转移,129例复发患者中46例(35.7%)复发时S100B升高。
  • 经典方法(单次S100B超过截断值)的敏感性和特异性分别为35.7%和92.5%。
  • 对S100B正常复发的患者,月度变化法的敏感性和特异性分别为41.1%和92.4%,可检出经典方法漏诊的额外复发。

临床怎么用

  • 高危黑色素瘤随访中,除关注S100B是否超过截断值外,还应关注其在正常范围内的月度上升趋势。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The role of S100B protein in detecting early melanoma relapses is controversial, since most metastasis occur within normal values of S100B. OBJECTIVE: The aim of this study was to assess the performance of S100B in detecting early disease progression in high-risk melanoma patients. METHODS: Retrospective cohort study including patients with an initial diagnosis of stage IIB, IIC and III melanoma between January 2003 and July 2013. All patients were followed up in accordance with an intensive protocol based on imaging studies and serum S100B levels every 3-6 months. We compared two methods to evaluate changes in S100B. The classic method referring to a single determination of S100B above the cut-off level at the time of metastasis, which was evaluated in all patients. And a new method based on monthly changes of S100, which was used in the setting of patients with S100B levels within the normal range. RESULTS: Overall, 289 of patients were followed up for 44 months (IQR 17-73) and 45% developed metastases. During the study period, 129 patients relapsed of which 46 (35.7%) present elevated values of S100B at the time of relapse. The classic method had a sensitivity and specificity of S100B protein of 35.7% and 92.5%, respectively. Furthermore, for the patients that relapsed with normal values of S100B, the new method was applied and showed a sensitivity and specificity of 41.1% and 92.4%, respectively, allowing to detect additional relapses that were missing by the classic method. CONCLUSION: During follow-up of high-risk melanoma patients, rising serum S100B values within the normal range can be an important clue to disease progression.

来源:J Eur Acad Dermatol Venereol,查看原文。版权归原作者所有。

引用

  1. Ertekin SS, Podlipnik S, Ribero S, et al. Monthly changes in serum levels of S100B protein as a predictor of metastasis development in high-risk melanoma patients. J Eur Acad Dermatol Venereol. 2020. PMID: 31967695. doi:10.1111/jdv.16212

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。